What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25‐year experience with 1,125 procedures

Abstract

This study demonstrated that CRS and HIPEC provide long-term survival irrespective of PC origin, and survival improves with experience. J. Surg. Oncol. 2016;113:796-803. © 2016 Wiley Periodicals, Inc.

Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years

“…In 2007, a systematic review of literature reported that observational studies demonstrated an improved OS in patients treated with HIPEC compared with historical controls . Despite the lack of randomized trials, there is an international agreement on the oncological benefits of HIPEC, which is nowadays the main treatment of peritoneal mesothelioma in adults . In the present study, the outcomes of HIPEC for the treatment of peritoneal mesothelioma in children are also encouraging.…”

“…Although CRS and HIPEC are feasible in young patients with peritoneal tumor spread, mortality and morbidity are dramatically high in this series. They are influenced by several factors including the multicentric nature of the series, histologic type of the tumor, local extension, presence of extraabdominal disease, completeness of cytoreduction, and postoperative treatment with chemotherapy and/or abdominal radiotherapy . In the present series, HIPEC was still administered despite CC‐2 resections in two patients and as third‐, fourth‐, and fifth‐line therapy in three, two, and one patients, respectively, although the results are usually dismal in that situation.…”

“…In conclusion, the role of CRS associated with HIPEC in children remains debated. Regardless of histology and PCI, the absence of disease outside the abdominal cavity and completeness of cytoreduction are the main prognosis factors in adults and children . In pediatrics, CRS and HIPEC are often considered in palliative situations, when no other treatment is available.…”

“…In these indications, complete CRS and HIPEC increase survival and disease‐free survival (DFS) in comparison with surgery associated with postoperative intravenous chemotherapy, but at the price of a significant morbidity rate (25–56%) . In a series including 1,125 patients treated with HIPEC, DFS at 10 years was 53% for pseudomyxoma, 14% for mesothelioma, 4% for carcinomatosis of ovarian origin, 10% for carcinomatosis of colorectal origin, and 9% for carcinomatosis of gastric origin …”

Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice

“…The action of 5-fluorouracil is therefore cell cycle specific. These characteristics limit the use of IP 5-fluorouracil to EPIC [19,[76][77][78][79]. 5-fluorouracil is not chemically compatible with other drugs in a mixed solution for infusion or instillation.…”